C T Brekelmans

Summary

Affiliation: Rotterdam Cancer Institute
Country: The Netherlands

Publications

  1. ncbi Family history of breast cancer and local recurrence after breast-conserving therapy. The Dutch Study Group on Local Recurrence after Breast Conservation (BORST)
    C T Brekelmans
    Department of Medical Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Eur J Cancer 35:620-6. 1999
  2. ncbi Risk factors and risk reduction of breast and ovarian cancer
    Cecile T M Brekelmans
    Department of Medical Oncology, Erasmus MC Daniel den Hood, Rotterdam, The Netherlands
    Curr Opin Obstet Gynecol 15:63-8. 2003
  3. ncbi Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk
    C T Brekelmans
    Department of Medical Oncology, Family Cancer Clinic, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 19:924-30. 2001
  4. ncbi Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation
    H Meijers-Heijboer
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    N Engl J Med 345:159-64. 2001
  5. pmc Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
    L C Verhoog
    Family Cancer Clinic, Department of Medical Oncology, Daniel den Hoed Cancer Centre, University Hospital Rotterdam, The Netherlands
    Br J Cancer 83:384-6. 2000
  6. ncbi MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC)
    M Kriege
    Rotterdam Family Cancer Clinic, Erasmus MC (University Medical Centre Rotterdam)/Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Fam Cancer 1:163-8. 2001
  7. ncbi Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients
    Mieke Kriege
    Department of Medical Oncology, Rotterdam Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 111:303-11. 2008
  8. pmc Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic
    Bernadette A M Heemskerk-Gerritsen
    Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg Oncol 14:3335-44. 2007
  9. ncbi Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?
    Cecile T M Brekelmans
    Lancet Oncol 7:191-3. 2006
  10. ncbi Hereditary breast cancer growth rates and its impact on screening policy
    Madeleine M A Tilanus-Linthorst
    Department of Surgical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Eur J Cancer 41:1610-7. 2005

Collaborators

Detail Information

Publications19

  1. ncbi Family history of breast cancer and local recurrence after breast-conserving therapy. The Dutch Study Group on Local Recurrence after Breast Conservation (BORST)
    C T Brekelmans
    Department of Medical Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Eur J Cancer 35:620-6. 1999
    ..Whilst this might be different for genetically predisposed patients, a positive family history does not appear to be a contra-indication for BCT...
  2. ncbi Risk factors and risk reduction of breast and ovarian cancer
    Cecile T M Brekelmans
    Department of Medical Oncology, Erasmus MC Daniel den Hood, Rotterdam, The Netherlands
    Curr Opin Obstet Gynecol 15:63-8. 2003
    ..Breast and ovarian cancer remain a significant burden for women living in the Western world. This paper reviews the risk factors and current strategies to prevent these diseases...
  3. ncbi Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk
    C T Brekelmans
    Department of Medical Oncology, Family Cancer Clinic, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 19:924-30. 2001
    ..The effectiveness of surveillance in high-risk women and especially BRCA1/2 mutation carriers is unknown. We present first results from a single large family cancer clinic...
  4. ncbi Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation
    H Meijers-Heijboer
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    N Engl J Med 345:159-64. 2001
    ..2; 95 percent confidence interval, 0.4 to 3.7; P=0.80). CONCLUSIONS: In women with a BRCA1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up...
  5. pmc Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
    L C Verhoog
    Family Cancer Clinic, Department of Medical Oncology, Daniel den Hoed Cancer Centre, University Hospital Rotterdam, The Netherlands
    Br J Cancer 83:384-6. 2000
    ..02). These data suggest that age at diagnosis of the first tumour should be taken into account when prophylactic mastectomy in BRCA1-patients is considered...
  6. ncbi MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC)
    M Kriege
    Rotterdam Family Cancer Clinic, Erasmus MC (University Medical Centre Rotterdam)/Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Fam Cancer 1:163-8. 2001
    ..The aim is to include 2,500 women. The study started on 1 November 1999. On 1 January 2002, more than 1,700 women, including 210 proven carriers of a BRCA1 or BRCA2 mutation, were included in the study...
  7. ncbi Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients
    Mieke Kriege
    Department of Medical Oncology, Rotterdam Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 111:303-11. 2008
    ..Data on distant disease-free interval (DDFI) and the localization of the first distant metastasis (DM) in BRCA1- and BRCA2-associated breast cancer (BC) patients are as yet scarcely available...
  8. pmc Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic
    Bernadette A M Heemskerk-Gerritsen
    Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Ann Surg Oncol 14:3335-44. 2007
    ..Prophylactic mastectomy (PM) results in the greatest BC risk reduction. Long-term data on the efficacy and sequels of PM are scarce...
  9. ncbi Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?
    Cecile T M Brekelmans
    Lancet Oncol 7:191-3. 2006
  10. ncbi Hereditary breast cancer growth rates and its impact on screening policy
    Madeleine M A Tilanus-Linthorst
    Department of Surgical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Eur J Cancer 41:1610-7. 2005
    ..It is recommended that the screening frequency should be adjusted according to a woman's age and a high-sensitive biannual test may be appropriate before the age of 40 years...
  11. pmc A family history of breast cancer will not predict female early onset breast cancer in a population-based setting
    Geertruida H de Bock
    Department of Epidemiology, Groningen University Medical Center, Groningen, The Netherlands
    BMC Cancer 8:203. 2008
    ..The aim of the current study was to determine the predictive value of a family history of cancer with regard to early onset of female breast cancer in a population based setting...
  12. ncbi Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition
    Mieke Kriege
    Rotterdam Family Cancer Clinic, Department of Medical Oncology, Erasmus Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    N Engl J Med 351:427-37. 2004
    ..We compared the efficacy of magnetic resonance imaging (MRI) with that of mammography for screening in this group of high-risk women...
  13. ncbi Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation
    Hanne Meijers-Heijboer
    Rotterdam Family Cancer Center, Department of Clinical Genetics, The Netherlands
    J Clin Oncol 21:1675-81. 2003
    ..To analyze the use of genetic testing, prophylactic mastectomy, and oophorectomy among women with breast and/or ovarian cancer from families with a BRCA1 or BRCA2 mutation...
  14. ncbi One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery)
    Litanja N Lodder
    Department of Medical Psychology, Erasmus University Rotterdam, Netherlands Institute for Health Sciences
    Breast Cancer Res Treat 73:97-112. 2002
    ..This might explain, why most women who underwent prophylactic mastectomy were satisfied with this decision, despite a perceived negative impact on body image, the intimate relationship and physical wellbeing...
  15. ncbi Tailoring breast cancer therapy to genetic status
    Caroline Seynaeve
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Centre, 3075 AE Rotterdam, Netherlands
    Lancet 365:1672-3. 2005
  16. ncbi Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients
    Madeleine M A Tilanus-Linthorst
    Department of Surgical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Breast Cancer Res Treat 95:117-23. 2006
    ..A higher incidence of contralateral breast cancer (CBC) has been reported in familial BC. Ascertainment bias may influence both the reported familial CBC and survival...
  17. ncbi Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition
    Mieke Kriege
    The Rotterdam Family Cancer Clinic, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, Netherlands
    Cancer 106:2318-26. 2006
    ....
  18. ncbi Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer
    Mieke Kriege
    Family Cancer Clinic, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Breast Cancer Res Treat 100:109-19. 2006
    ..In the current subsequent study we investigated whether these results are influenced by age, a BRCA1/2 mutation, menopausal status and breast density...
  19. ncbi Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer
    Paul A M Meeuwissen
    Family Cancer Clinic, The Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Erasmus University Medical Centre Rotterdam, Room H585, Dr Molewaterplein 40, 3000 CC Rotterdam, The Netherlands
    Gynecol Oncol 97:476-82. 2005
    ..Women at high risk of ovarian cancer are currently offered two options: either surveillance or prophylactic bilateral salpingo-oophorectomy. The efficacy and outcome of surveillance remain unclear...